SciClone Pharmaceuticals, Inc.
SCICLONE PHARMACEUTICALS INC (Form: 4, Received: 06/22/2017 16:16:16)
FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Blobel Friedhelm
2. Issuer Name and Ticker or Trading Symbol

SCICLONE PHARMACEUTICALS INC [ SCLN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
President & CEO
(Last)          (First)          (Middle)

950 TOWER LANE, SUITE 900
3. Date of Earliest Transaction (MM/DD/YYYY)

6/20/2017
(Street)

FOSTER CITY, CA 94404
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   6/20/2017     M (1)    30000   A $3.55   152209   D    
Common Stock   6/20/2017     S (1)    30000   D $10.9033   122209   D    
Common Stock   6/20/2017     M (1)    40000   A $3.55   162209   D    
Common Stock   6/20/2017     S (1)    40000   D $10.9132   122209   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy)   (2) $3.55   6/20/2017     M         30000      (3) 3/5/2020   Common Stock   30000   $0   67654   D    
Non-Qualified Stock Option (right to buy)   (2) $3.55   6/20/2017     M         40000      (3) 3/5/2020   Common Stock   40000   $0   27654   D    

Explanation of Responses:
(1)  The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
(2)  Granted under the Issuer's 2005 Equity Incentive Plan.
(3)  25% of each shares vest one year from the date of grant, of March 5, 2010, and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Blobel Friedhelm
950 TOWER LANE, SUITE 900
FOSTER CITY, CA 94404
X
President & CEO

Signatures
/s/ Friedhelm Blobel, Ph.D. 6/22/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.